Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.

Tonk, E C M; Gurwitz, D; Maitland-van der Zee, A-H; Janssens, A C J W

Tonk, E C M; Gurwitz, D; Maitland-van der Zee, A-H; Janssens, A C J W.

Affiliation

Tonk ECM; Department of Clinical Genetics/EMGO Institute for Health and Care Research, Section Community Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Gurwitz D; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Maitland-van der Zee AH; Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology &Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Janssens ACJW; Department of Clinical Genetics/EMGO Institute for Health and Care Research, Section Community Genetics, VU University Medical Center, Amsterdam, The Netherlands.

Pharmacogenomics J ; 17(4): 386-392, 2017 07.

Article in En | MEDLINE | ID: mdl-27168098

Subject(s)

Drug-Related Side Effects and Adverse Reactions/genetics; Dideoxynucleosides/adverse effects; Drug Hypersensitivity/genetics; Genetic Testing/methods; Genetic Variation/genetics; HLA-B Antigens/genetics; Humans; Pharmacogenetics/methods; Simvastatin/adverse effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Pharmacogenomics J Journal subject: BIOLOGIA MOLECULAR / FARMACOLOGIA Year: 2017 Document type: Article Affiliation country: Netherlands Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google